Jazz Pharmaceuticals PLC $JAZZ Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC increased its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 1.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,171,755 shares of the specialty pharmaceutical company’s stock after purchasing an additional 16,757 shares during the period. Geode Capital Management LLC owned 1.94% of Jazz Pharmaceuticals worth $124,366,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Hurley Capital LLC acquired a new position in shares of Jazz Pharmaceuticals during the first quarter valued at $25,000. Picton Mahoney Asset Management increased its holdings in shares of Jazz Pharmaceuticals by 2,445.5% in the 1st quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock worth $34,000 after acquiring an additional 269 shares during the period. SVB Wealth LLC bought a new stake in Jazz Pharmaceuticals in the 1st quarter valued at about $36,000. Hantz Financial Services Inc. boosted its stake in Jazz Pharmaceuticals by 471.4% during the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 297 shares during the period. Finally, Geneos Wealth Management Inc. grew its position in Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 137 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of a number of recent analyst reports. Bank of America lifted their price target on Jazz Pharmaceuticals from $230.00 to $247.00 and gave the company a “buy” rating in a report on Tuesday. Truist Financial lifted their target price on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a “buy” rating in a research note on Thursday, August 28th. JPMorgan Chase & Co. decreased their price target on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a research note on Monday, October 27th. Wall Street Zen upgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Jazz Pharmaceuticals in a report on Wednesday, October 8th. Fourteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $195.07.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the company’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total value of $771,720.00. Following the transaction, the director owned 429,973 shares of the company’s stock, valued at approximately $55,303,127.26. This represents a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Robert Iannone sold 7,159 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of $168.26, for a total value of $1,204,573.34. Following the sale, the executive vice president owned 72,628 shares of the company’s stock, valued at $12,220,387.28. This trade represents a 8.97% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 18,659 shares of company stock worth $2,729,853. 4.30% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Trading Down 2.5%

Shares of Jazz Pharmaceuticals stock opened at $176.08 on Thursday. The business has a fifty day simple moving average of $136.90 and a 200-day simple moving average of $121.57. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $182.99. The firm has a market cap of $10.70 billion, a price-to-earnings ratio of -26.16, a price-to-earnings-growth ratio of 8.49 and a beta of 0.29. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 EPS for the quarter, topping the consensus estimate of $5.87 by $2.26. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm had revenue of $1.13 billion for the quarter, compared to analysts’ expectations of $1.11 billion. During the same period in the previous year, the business earned $6.54 earnings per share. Jazz Pharmaceuticals’s revenue for the quarter was up 6.7% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. On average, equities analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.